May S. Elsherif

4.5 Km, Ring Road
Ismailia, IS 41111, Egypt

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Pre-existing antibodies predict protection while mucosal inflammation correlates with symptomatic Bordetella pertussis infection.

Pre-existing antibodies predict protection while mucosal inflammation correlates with symptomatic Bordetella pertussis infection.

Journal: medRxiv : the preprint server for health sciences

Published: July 17, 2026

Systemic and Mucosal Antibody Correlates of Protection Against Bordetella pertussis in a Controlled Human Infection Model.

Systemic and Mucosal Antibody Correlates of Protection Against Bordetella pertussis in a Controlled Human Infection Model.

Journal: medRxiv : the preprint server for health sciences

Published: July 03, 2026

A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420.

A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420.

Journal: medRxiv : the preprint server for health sciences

Published: June 29, 2026

Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Journal: The lancet. HIV

Published: February 25, 2026

Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

Journal: Vaccine

Published: July 30, 2025

Human Metapneumovirus Epidemiology Among Middle-aged and Older Adults Hospitalized With Acute Respiratory Infection.

Human Metapneumovirus Epidemiology Among Middle-aged and Older Adults Hospitalized With Acute Respiratory Infection.

Journal: The Journal of infectious diseases

Published: July 16, 2025

Relationship Between Frailty and Respiratory Syncytial Virus Infection in Hospitalized Older Adults.

Relationship Between Frailty and Respiratory Syncytial Virus Infection in Hospitalized Older Adults.

Journal: Open forum infectious diseases

Published: February 19, 2025

Oseltamivir Reduces 30-Day Mortality in Older Adults With Influenza: A Pooled Analysis From the 2012-2019 Serious Outcomes Surveillance Network of the Canadian Immunization Research Network.

Oseltamivir Reduces 30-Day Mortality in Older Adults With Influenza: A Pooled Analysis From the 2012-2019 Serious Outcomes Surveillance Network of the Canadian Immunization Research Network.

Journal: Open forum infectious diseases

Published: December 11, 2024

Predicting major clinical events among Canadian adults with laboratory-confirmed influenza infection using the influenza severity scale.

Predicting major clinical events among Canadian adults with laboratory-confirmed influenza infection using the influenza severity scale.

Journal: Scientific reports

Published: October 16, 2023

Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN).

Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN).

Journal: Vaccine

Published: June 15, 2023

Leveraging Influenza Virus Surveillance From 2012 to 2015 to Characterize the Burden of Respiratory Syncytial Virus Disease in Canadian Adults ≥50 Years of Age Hospitalized With Acute Respiratory Illness.

Leveraging Influenza Virus Surveillance From 2012 to 2015 to Characterize the Burden of Respiratory Syncytial Virus Disease in Canadian Adults ≥50 Years of Age Hospitalized With Acute Respiratory Illness.

Journal: Open forum infectious diseases

Published: April 06, 2023

Benefits of Combining Molecular Biology and Controlled Human Infection Model Methodologies in Advancing Vaccine Development.

Benefits of Combining Molecular Biology and Controlled Human Infection Model Methodologies in Advancing Vaccine Development.

Journal: Journal of molecular biology

Published: January 31, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026